Multiple sclerosis (MS) shares some risk genes with other disorders hallmarked by an autoimmune pathogenesis, most notably IL2RA and CLEC16A. We analyzed 10 single-nucleotide polymorphisms (SNPs) in nine risk genes, which recently emerged from a series of non-MS genome-wide association studies (GWAS), in a Spanish cohort comprising 2895 MS patients and 2942 controls. We identified two SNPs associated with MS. The first SNP, rs6859219, located in ANKRD55 (Chr5), was recently discovered in a meta-analysis of GWAS on rheumatoid arthritis (RA), and emerged from this study with genome-wide significance (odds ratio (OR) ¼ 1.35; P ¼ 2.3 Â 10 À9 ). The second SNP, rs12785878, is located near DHCR7 (Chr11), a genetic determinant of vitamin D insufficiency, and showed a size effect in MS similar to that recently observed in Type 1 diabetes (T1D; OR ¼ 1.10; P ¼ 0.009). ANKRD55 is a gene of unknown function, and is flanked proximally by the IL6ST --IL31RA gene cluster. However, rs6859219 did not show correlation with a series of haplotype-tagging SNPs covering IL6ST --IL31RA, analyzed in a subset of our dataset (D 
INTRODUCTION
Multiple sclerosis (MS) is a heterogeneous chronic inflammatory disease of the central nervous system driven by a complex pathogenesis characterized by demyelination and neurodegeneration. Extensive epidemiological data on familial aggregation of the disease, in conjunction with twin and adoptee studies, argue for a polygenic, multifactorial mechanism. 1 Since the advent of genome-wide association studies (GWAS), swift progress has been made in identification of risk loci for MS. Most allelic risk variants identified to date exhibit low penetrance and high frequency of the risk allele in unaffected subjects, bringing about modest odds ratios (ORs) that rarely exceed 1.2---exception made for the HLA class II DR*15 haplotype that is identifiable with ORs of 2 --3.4. 2 Comparison of data from GWAS on various autoimmune/chronic inflammatory disorders has been shown to be instrumental in uncovering both disease-specific and shared genetic risk factors. The latter of these are indicative for intersection of common pathogenic pathways across a spectrum of diverse conditions, and are therefore arguably of greater translational interest. The archetypal, shared autoimmune risk gene is IL2RA that demonstrates susceptibility effects in MS, Type 1 diabetes (T1D), Graves' disease and rheumatoid arthritis (RA), albeit with divergent allelic association patterns. 1 In an attempt to identify additional pan-autoimmune loci of relevance to MS, we performed a screen of 10 risk singlenucleotide polymorphisms (SNPs) located in or nearby nine genes, that is, AFF3, ANKRD55, CCR6, CYP2R1, DHCR7, IL2RA, IL10, PRDM1 and PXK, all of which emerged recently from GWAS on a number of diseases and conditions different from MS (Table 1) . The screen was performed in a Spanish Caucasian cohort comprising 2895 MS patients and 2942 controls, composed of four geographically separate collections; North of Spain (Basque Country; 786 MS patients and 718 controls), South of Spain (Andalucía; 1104 MS patients and 1225 controls), East of Spain (Catalunya; 466 MS patients and 464 controls) and Central Spain (Madrid; 539 cases and 535 controls). This cohort was recently used to successfully identify allelic risk variants in the KIF5A, CD226 and SH2B3 loci, originally discovered in RA and T1D, as MS risk factors. 3 We provide here a brief overview of the studies that have enabled the discovery of the nine autoimmune risk genes referred to above. AFF3 emerged originally from a GWAS on T1D, though its association was short of genome-wide significance; rs11676922 (or its genetic proxy rs1160542 (D 0 ¼ 1, r 2 ¼ 1)) located 48 kb 5 0 from the AFF3 transcription initiation site was subsequently identified and robustly validated as risk locus for RA and juvenile idiopathic arthritis. 4 --7 rs6859219 located in the ANKRD55 gene was identified in a meta-analysis of RA GWAS, and successfully replicated in the same study. 6 An intronic SNP, rs2301436 in FGFR10P, which flanks the CCR6 gene locus was first identified in Crohn's disease (CD). 8 More recently, rs3093023 in the promoter area of CCR6 at 1.9 kb from the transcription initiation site emerged as risk factor for RA in populations of European ancestry, while rs3093024, also located in the CCR6 promoter at 1.5 kb upstream from rs3093023 and in perfect linkage disequilibrium (LD) with it (D 0 ¼ 1, r 2 ¼ 1) in the European population, was identified as RA risk factor in the Japanese population. 6, 9 Further evidence for the generalized involvement of the CCR6 gene region in autoimmune disease risk comes from two independent GWAS on vitiligo each of which identified strongly associated SNPs located 30 --175 kb upstream from CCR6. 10, 11 The CYP2R1 and DHCR7 loci reached genome-wide significance in two GWAS on vitamin D insufficiency.
12,13 CYP2R1 rs10741657 and DHCR7 rs12785878 were found to be associated with T1D, a condition associated with vitamin D deficiency. 14, 15 Given the welldocumented candidacy of vitamin D as key factor in the pathogenesis of MS, both the SNPs were included in the present association study. 16 An intronic SNP in IL2RA, rs12722489, emerged from the first GWAS in MS as one of the first ever non-HLA MS risk polymorphisms to be identified. 17 This association was subsequently shown to be conditional to LD with a primarily associated SNP, rs2104286, located in the same intron. 18 A new IL2RA SNP, rs706778, that is located in very close vicinity, that is at only 96 bp from rs2104286, but nevertheless occurs in only partial LD with it (D 0 ¼ 0.89, r 2 ¼ 0.19), was identified in a RA GWAS, and was included in the present analysis to verify whether it may constitute a novel marker for association with MS. 6 The T allele of rs3024505 located 1.04 kb 3 0 from the polyadenylation site of IL10 has been identified as genetic risk factor in a series of GWAS on ulcerative colitis (UC), CD and systemic lupus erythematosus (SLE). 19 --22 Of note, the alternate C allele of the same SNP was found to be associated with enhanced genetic risk for contracting T1D (see Table 1 ). 20, 23 The PRDM1 gene region was identified as susceptibility locus for CD, UC, SLE and RA through meta-analyses of GWAS coupled to replication exercises in independent sample sets. 8, 22, 24, 25 The most strongly associated SNPs identified in the CD and UC studies, rs7746082 and rs6911490, respectively, are in partial LD (D 0 ¼ 0.76, r 2 ¼ 0.265), separated by a stretch of 87 kb and are located 5 0 from PRDM1.
8,25
Similarly, the PRDM1 SNPs emerging from the RA and SLE studies, rs548234 and rs6568431, respectively, are 21 kb apart, occur in LD (D 0 ¼ 0.92, r 2 ¼ 0.69), and both are located 3 0 from PRDM1.
22,24
Neither of the UC/CD PRDM1 SNPs occurs in LD with any of the RA/SLE SNPs (D 0 p0.54, r 2 p0.09), an observation that may be indicative for the existence of independent susceptibility effects conferred either by allelic variants at the PRDM1 locus, or at any neighboring locus within reach of these discrete LD patterns. Thus, in order to ascertain more complete assessment of the genetic diversity at PRDM1, both the RA rs548234 and the CD rs7746082 SNPs (Table 1) were genotyped. Finally, PXK was disclosed as risk locus in GWAS on SLE and RA, and the SNP identified in the latter screen was included in the present analysis. 6, 26 RESULTS AND DISCUSSION The overall genotyping success rate amounted to 98.4%. Genotypes of all SNPs in cases and controls were in Hardy --Weinberg equilibrium (P410 À2 ). Power was calculated for detection of genetic effects based on published ORs (Table 2) , and amounted to X77% for seven SNPs but was p43% for three SNPs. This was either due to the very-low published ORs for the association of SNPs in the vitamin D pathway genes CYP2R1 and DHCR7 with T1D, or to the low risk allele frequency of the PXK SNP.
6,14 Notwithstanding, we identified a moderately significant association of DHCR7 rs12785878 with MS in the full cohort (OR ¼ 1.10; 95% confidence interval (CI) ¼ 1.02 --1.19; P CMH ¼ 0.009) ( Table 2 ). The only other, though much stronger, association found was that with the ANKRD55 SNP rs6859219 (OR ¼ 1.26; 95% CI ¼ 1.16 --1.38; P CMH ¼ 1.9 Â 10
À7
). Figure 1 shows that this association was detected at nominally significant levels (Po0.05) in the South, North and East of Spain subsets, but not in the Central Spain subset. As a consequence, the Breslow-Day test for P-values refer to the full combined GWAS (genomewide association studies) + replication dataset of cases and controls, while ORs (95% CI) are based on the replication dataset only (6768 cases, 8806 controls). 14 heterogeneity in effect between the population strata was weakly significant at P BD ¼ 0.02. Following removal of the Central Spain subset, the C allele of rs6859219 was associated with MS in the absence of heterogeneity (OR ¼ 1.35; 95% CI ¼ 1.22 --1.49; P CMH ¼ 2.3 Â 10 À9 ; P BD ¼ 0.66). Clearly, the size effect of this association positions it within the realm of genome-wide significance (P ¼ 5 Â 10 À7 ). 27 Although none of the other SNPs were associated with susceptibility to MS, the T allele of IL10 SNP rs3024505, which was recently found to be associated with UC, CD and SLE, displayed a non-significant tendency towards association (OR ¼ 1.09; 95% CI ¼ 0.98 --1.22; P CMH ¼ 0.10), 19 --22 and a similar trend was observed for AFF3 rs11676922 (Table 2) . ANKRD55(5q11) codes for the ankyrin repeat domain 55 protein of which the function and natural cell types of expression are undocumented. Publicly available human transcriptome data indicate ANKRD55 expression in ovary, testes, endometrium and, likely of higher relevance to autoimmune disease, in resting CD4 þ T cells (http://www.amazonia.transcriptome.eu). Rs6859219 is located in the seventh intron of the ANKRD55 gene, and does not seem to exert functional effects in terms of splicing and transcription factor binding site modification (SNP Function Prediction at http://snpinfo.niehs.nih.gov). The ANKRD55 gene area extending from around intron 6 to exon 9 is characterized by a low degree of LD due to occurrence of a series of recombination hotspots (425cM/Mb) in this region of the gene. Two other candidates in this chromosome area, the IL31RA --IL6ST genes, though functionally attractive, are located outside the region of LD, at a distance of 158 kb 3 0 from ANKRD55. In a recent study, we analyzed 13 haplotype-tagging SNPs in the IL6ST --IL31RA cluster for association with MS in the Spanish --Basque collection, and did not find evidence for association. 28 However, the availability of this data for 400 cases and 374 control subjects allowed us to analyze LD patterns between rs6859219 and each of the 13 SNPs, which confirmed absence of correlation (r 2 values ranging between 0.001 and 0.011; D 0 values ranging between 0.06 and 0.31). Pending future independent confirmation, ANKRD55, rather than IL6ST --IL31RA, may therefore constitute the actual susceptibility gene. The ankyrin repeat is a 33-residue sequence motif involved in protein --protein interaction that is found in numerous proteins, and accounts for an extraordinary variety of biological activities. 29 Ankyrin repeat proteins involved in human disease include, among others, p16 in cancer, as well as mutations in the Notch protein associated with the neurological disorder 'cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy'. 30, 31 Notch signaling is involved in immune responses and tissue repair mechanisms pertinent to MS. 32 The second significantly associated gene arising from this study, albeit with much smaller genetic effect, DHCR7, was recently discovered in two GWAS on vitamin D insufficiency. 12, 13 Rs12785878 is located in the second intron of the NADSYN1 gene, Power was calculated for detection of multiplicative allelic effects at an a level of 0.05 using the ORs for association of each SNP (single-nucleotide polymorphism) with the diseases included in Table 1 , based on a sample number of 2895 MS (multiple sclerosis) patients and 2942 controls (CATS power calculator at http://www.sph.umich.edu/csg/abecasis/CaTS/).
b P BD was weakly significant due to an opposite allelic trend seen in the Central Spain dataset. Upon exclusion of this dataset, the C allele of rs6859219 was associated with MS (C allele frequency of 80.4% in MS patients, and of 75.3% in controls) in the remaining cohort (2356 MS patients, 2407 controls) with P CMH ¼ 2.3 Â 10
À9
, OR ¼ 1.35 (95% CI ¼ 1.22 --1.49), in the absence of stratum-dependent heterogeneity (P BD ¼ 0.66).
ANKRD55 and DHCR7 are MS risk loci I Alloza et al at a position 8 kb 5
0 from the transcription initiation site of DHCR7, and is not predicted to exert functional effects such as transcription factor binding site and splicing modification (SNP Function Prediction at http://snpinfo.niehs.nih.gov). DHCR7 codes for the enzyme delta-7-sterol reductase (EC 1.3.1.21), which converts 7-dehydrocholesterol (7-DHC) to cholesterol. Vitamin D 3 is made in the skin when 7-DHC reacts with ultraviolet light. Thus, the conversion of 7-DHC by the gene product of DHCR7 removes the substrate 7-DHC from the synthetic pathway for the production of vitamin D 3 .
12,13 The G allele of rs12785878, which is associated with lower levels of 25(OH)D and risk for T1D, enhances susceptibility to MS (Table 2, Figure 1 ).
14 Several studies have analyzed vitamin D metabolic pathway genes as determinants of risk for MS, generally with negative outcomes. 33 --36 Regulation of the MS-associated HLA-DRB1*1501 allele by vitamin D has been reported. 37 However, given the only very recent discovery of the functional link between DHCR7 and vitamin D insufficiency, earlier studies have not addressed allelic variation in this gene. Hence, this study is the first to demonstrate a genetic link between an important regulator of vitamin D levels, DHCR7, and risk for MS. Replication is needed to ascertain this association with genome-wide level of significance.
The rs706778 SNP located in the first intron of the IL2RA gene that emerged from a GWAS on RA, 6 appeared not be associated with MS (Table 2) . We also typed the well-established MS risk SNP 18 rs2104286 in 1866 Spanish cases and 1855 geographically matched controls, and found that it was highly associated with the disease at P CMH ¼ 6.8 Â 10 À7 (OR ¼ 1.36, 95% CI ¼ 1.20 --1.51), while in the same subset of samples rs706778 was not associated with P CMH ¼ 0.95 (OR ¼ 1.00; 95% CI ¼ 0.91 --1.10). Genetic heterogeneity in association patterns of SNPs in IL2RA with autoimmune disease has been documented, and this may lay at the basis of this effect. 38 In conclusion, our study has revealed two new susceptibility loci for MS that have not been reported before. Though the genetic association of DHCR7 with MS does not reach genomewide significance, ANKRD55 shows an unusually strong association with MS in this Spanish dataset (Table 2) . A fine mapping of this locus is currently being performed in order to gather insight into the genetic and functional mechanism by which it operates.
PATIENTS AND METHODS
Demographic and clinical characteristics of the collection genotyped in the present study have been described recently. 3, 39 Patients and control subjects were included in the study based upon written informed consent. Briefly, the sample collection analyzed consisted of 2895 MS patients diagnosed according to Poser's criteria 40 and 2942 healthy controls, mostly blood donors, matched by age, gender, ethnicity and place of recruitment. The female/male ratio amounts to 2 with a mean age of 30 years at onset and with 75% of patients suffering relapsing-remitting MS, while 5% of patients were diagnosed to suffer from the primary-progressive clinical form. SNPs were genotyped using the iPLEX Sequenom MassARRAY platform in the Spanish National Genotyping Center (CEGEN, Santiago de Compostela, http://www.cegen.org) following the quality control steps previously described. 3, 39 Raw data were analyzed for comparison of allele and genotype counts using PLINK version 1.07. 41 The Cochran --Mantel --Haenszel test implemented in PLINK was used to calculate an average OR arising from the combination of distinct case-control datasets. Heterogeneity of ORs was assessed through the Breslow-Day test, also implemented in PLINK. A w 2 test was used to ascertain that genotype distributions fulfilled the criteria of Hardy --Weinberg equilibrium. P-values are uncorrected. Power was calculated using the CATS power calculator at http://www.sph.umich.edu/csg/abecasis/CaTS/. 42 LD patterns between SNPs, as described above, were analyzed with the SNP Annotation and Proxy Search tool at http://www.broadinstitute.org/mpg/snap/. 43 
